

## Torrent Pharmaceuticals Limited

Instrument	Amount (Rs. Crore)	Rating Action September 2016
Long Term - Cash Credit	Enhanced from 1,005.0* to 1,795.0	[ICRA]AA reaffirmed/assigned (outlook revised to positive from stable)
Long Term - Term Loans	Revised from 1,900.0 to 1,171.0	[ICRA]AA reaffirmed (outlook revised to positive from stable)
Long/Short Term - Unallocated	Revised from 95.0 to Nil	-
Commercial Paper	60 .0	[ICRA]A1+ reaffirmed
NCD	1000.0	[ICRA]AA reaffirmed (outlook revised to Positive)

*\*Previous outstanding was Rs. 995 crore for long term cash credit facility*

ICRA has reaffirmed/assigned [ICRA]AA (pronounced as ICRA double A) to the revised/enhanced Rs. 1,795 crore Cash Credit, Rs. 1,171 crore term loans and to Rs. 1,000 crore existing NCD programme of Torrent Pharmaceuticals Limited. ICRA has also reaffirmed [ICRA]A1+(pronounced as ICRA A one plus) ratings to the Rs. 60 crore Commercial Paper programme of the company. ICRA has revised the outlook from Stable to Positive.

The rating takes into account TPL's established market position in the Indian domestic pharmaceutical market, strengthened by the acquisition of the identified domestic branded formulations business of Elder Pharma. The rating is supported by TPL's profitable and expanding international operations and healthy cash flow generation ability of existing and acquired business. The recent acquisition provides TPL a strong foothold in the nutraceuticals/women's healthcare segment with market leading brands such as *Shelcal*, and *Chymoral*. TPL's existing domestic branded business also enjoys strong market position and is ranked amongst the top 10 Companies in CVS (CardioVascular), CNS (Central Nervous System) and GI (Gastro Intestinal) therapeutic areas. Further, recent acquisition of Zyg Pharma comprising of its USFDA approved manufacturing facility will enable Torrent Pharma to diversify into niche Dermatology segment especially in the developed markets like US and Europe and emerging markets of India and Brazil. To build pipeline for future launches in both domestic and international business, TPL is also investing into R&D.

Its international operations that are in scale up mode have shown consistent profitability at an aggregate level, although ICRA notes that TPL's position in certain individual international markets is yet to achieve meaningful size with consistent profitability track record for each of these markets. The US operations has shown strong growth over the last few years and with planned launches over the next few years, ICRA expects the same to contribute significantly to its International operations profitability. TPL has established itself as a quality CRAMS partner through various tie-ups with global pharma majors that will also aid revenue growth and profitability. The company's ability to sustain its performance across multiple geographies and its ability to scale up the acquired business would remain critical to sustaining its financial profile.

The debt funded acquisition has led to higher debt levels and interest outgo, although the capital structure and coverage indicators remain comfortable by virtue of strong operating margins and healthy net cash accruals. The company has surplus cash and liquid investments to the tune of Rs. 825 crore against total debt of Rs. 2,365 crore as on March 2016. The revision of outlook to positive reflects ICRA's expectation that the financial profile will further improve owing to healthy cash flow generation and moderate capex plans. Furthermore, while ICRA expects TPL to sustain its credit profile through its future investment plans, any significant investment / acquisition would be evaluated by ICRA on a case-by-case basis for its impact on the credit profile

### Company Profile

Torrent Pharmaceuticals Limited (TPL) is a strong player in the domestic market with a strong presence in the fast growing, lifestyle related therapeutic segments like Cardiovascular (CVS) and Central Nervous System (CNS). The company has an arrangement for the manufacture and supply of insulin for the Indian market with



Novo Nordisk. The export business of TPL is carried out both by its foreign subsidiaries as well as directly by the parent company.

In FY 2006, TPL acquired Heumann Pharma GmbH & Co. Generica KG (Heumann), a Pfizer group company, engaged in generic medicines marketing in Germany. In June 2014, TPL acquired Elder Pharma's branded domestic formulation business in India and Nepal for a consideration of Rs. 2004 crore. Elder's acquired business comprises a portfolio of 30 brands including leading brands for women's healthcare (WHC), pain management, wound care and nutraceuticals therapeutic segment. The acquisition has complemented TPL's existing therapies and will provide a strong foothold in the nutraceuticals/WHC segment.

With the acquisition of ZYG Pharma's US FDA approved facility, the company will embark into the niche dermatological segment, especially in the developed markets of North America and Europe, as well as in the emerging markets of India and Brazil. TPL markets both branded (to semi-regulated markets) and unbranded generics (to regulated markets), and also participates in the institutional segment of export markets. Among its key branded generics markets are India and Brazil, while its generic generics business spans Germany and USA. The company has USFDA and EU approved formulations and API facilities. It is vertically integrated to manage costs.

#### **Recent Results**

TPL recorded Operating Income of Rs. 6676.4 crore and Rs. 1,545.0 crore and PAT margin of 25.8% and 18.9% during FY 2016 and Q1 FY2017 respectively.

**September 2016**

*For further details, please contact:*

**Analyst Contacts:**

**Mr. Subrata Ray** (Tel. No. +91 22 6114 3408)  
subrata@icraindia.com

**Gaurav Jain** (Tel. No. +91 20 2556 1194 )  
gaurav.jain@icraindia.com

**Relationship Contacts:**

**Mr. L. Shivakumar**, (Tel. No. +91 22 6114 3406)  
shivakumar@icraindia.com

© Copyright, 2016, ICRA Limited. All Rights Reserved  
Contents may be used freely with due acknowledgement to ICRA

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.

**Registered Office****ICRA Limited**

1105, Kailash Building, 11th Floor, 26, Kasturba Gandhi Marg, New Delhi 110001  
Tel: +91-11-23357940-50, Fax: +91-11-23357014

**Corporate Office****Mr. Vivek Mathur**

Mobile: +91 9871221122

Email: [vivek@icraindia.com](mailto:vivek@icraindia.com)

Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002  
Ph: +91-124-4545310 (D), 4545300 / 4545800 (B) Fax; +91- 124-4050424

**Mumbai****Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: [shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

3rd Floor, Electric Mansion  
Appasaheb Marathe Marg, Prabhadevi  
Mumbai—400025,  
Board : +91-22-61796300; Fax: +91-22-24331390

**Kolkata****Mr. Jayanta Roy**

Mobile: +91 9903394664

Email: [jayanta@icraindia.com](mailto:jayanta@icraindia.com)

A-10 & 11, 3rd Floor, FMC Fortuna  
234/3A, A.J.C. Bose Road  
Kolkata—700020  
Tel +91-33-22876617/8839 22800008/22831411,  
Fax +91-33-22870728

**Chennai****Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: [jayantac@icraindia.com](mailto:jayantac@icraindia.com)

5th Floor, Karumuttu Centre  
634 Anna Salai, Nandanam  
Chennai—600035  
Tel: +91-44-45964300; Fax: +91-44 24343663

**Bangalore****Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: [jayantac@icraindia.com](mailto:jayantac@icraindia.com)

'The Millenia'  
Tower B, Unit No. 1004, 10th Floor, Level 2 12-14, 1 & 2,  
Murphy Road, Bangalore 560 008  
Tel: +91-80-43326400; Fax: +91-80-43326409

**Ahmedabad****Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: [shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

907 & 908 Sakar -II, Ellisbridge,  
Ahmedabad- 380006  
Tel: +91-79-26585049, 26585494, 26584924; Fax:  
+91-79-25569231

**Pune****Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: [shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

5A, 5th Floor, Symphony, S.No. 210, CTS 3202, Range  
Hills Road, Shivajinagar, Pune-411 020  
Tel: + 91-20-25561194-25560196; Fax: +91-20-  
25561231

**Hyderabad****Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: [jayantac@icraindia.com](mailto:jayantac@icraindia.com)

4th Floor, Shobhan, 6-3-927/A&B. Somajiguda, Raj  
Bhavan Road, Hyderabad—500083  
Tel:- +91-40-40676500